文献速递银屑病与炎症性皮肤病

银屑病与糖尿病风险:一项前瞻性人群队列研究

Psoriasis and the risk of diabetes: A prospective population-based cohort study.
PubMed 文献 · J Am Acad Dermatol · 2017-11-08

该前瞻性人群队列研究纳入英国8124例银屑病成人和76599例无银屑病成人,随访约4年,发现银屑病患者糖尿病累积发生率3.44%,无银屑病者为2.44%;调整年龄、性别和BMI后,BSA受累≥10%者糖尿病风险显著升高(HR 1.64,95%CI 1.23-2.18),BSA≤2%者HR 1.21(95%CI 1.01-1.44),3%-10%者无显著关联。

要点

  • BSA≥10%者糖尿病风险HR 1.64(95%CI 1.23-2.18)。
  • 临床可测量银屑病BSA以指导糖尿病预防。

核心结论

  • 银屑病患者中,直接评估的BSA受累≥10%与糖尿病风险显著升高独立相关。
  • BSA≤2%者糖尿病风险轻度升高(HR 1.21,95%CI 1.01-1.44),3%-10%者无显著关联。

研究设计与样本

  • 前瞻性、人群为基础的队列研究,来自英国,纳入8124例银屑病成人和76599例无银屑病成人,随访约4年。

主要发现

  • 银屑病组糖尿病发病280例(3.44%),无银屑病组1867例(2.44%)。
  • 全球估计银屑病患者每年较无银屑病者新增125650例T2DM诊断。

关键数值与推荐

  • BSA受累≤2%:HR 1.21(95%CI 1.01-1.44)。
  • BSA受累3%-10%:HR 1.01(95%CI 0.81-1.26)。
  • BSA受累≥10%:HR 1.64(95%CI 1.23-2.18)。

临床怎么用

  • 临床医生可测量银屑病患者的BSA受累面积,以针对性地开展糖尿病预防工作。

局限性

  • 随访时间相对较短,且排除了 prevalent 病例,可能掩盖了银屑病范围较小患者的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data evaluating the impact of objectively measured psoriasis severity on type 2 diabetes mellitus (T2DM) risk are lacking. OBJECTIVE: To determine the risk for T2DM in patients with psoriasis compared with that in adults without psoriasis, stratified by categories of directly assessed body surface area (BSA) affected by psoriasis. METHODS: A prospective, population-based, cohort study from the United Kingdom in which 8124 adults with psoriasis and 76,599 adults without psoriasis were followed prospectively for approximately 4 years. RESULTS: There were 280 incident cases of diabetes in the psoriasis group (3.44%) and 1867 incident cases of diabetes in those without psoriasis (2.44%). After adjustment for age, sex and body mass index, the hazard ratios for development of incident diabetes were 1.21 (95% confidence interval [CI], 1.01-1.44), 1.01 (95% CI, 0.81-1.26), and 1.64 (95% CI, 1.23-2.18) in the groups with 2% or less of their BSA affected, 3% to 10% of their BSA affected, and 10% or more of their BSA affected compared with in the groups without psoriasis, respectively (P = .004 for trend). Worldwide, we estimate an additional 125,650 new diagnoses of T2DM per year in patients with psoriasis as compared with in those without psoriasis. LIMITATIONS: Relatively short-term follow-up and exclusion of prevalence cases, which may have masked associations in patients with less extensive psoriasis. CONCLUSION: Clinicians may measure BSA affected by psoriasis to target diabetes prevention efforts for patients with psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: A prospective population-based cohort study. J Am Acad Dermatol. 2017. PMID: 29128465. doi:10.1016/j.jaad.2017.10.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。